p-PBPK models that incorporated pregnancy-induced changes in UGT1A1, UGT1A4 and UGT1A9 expression/activity, or assumed no change for UGT2B7, accurately predicted the pharmacokinetics of most UGT-metabolized drugs. These findings enhance our understanding of phase II metabolism during pregnancy and may support dose adjustment for those drugs in the future.
Saffaf et al. (Wed,) studied this question.